Sunho Biologics (HKSE:02898) Other Current Receivables: HK$7.13 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02898 Sunho Biologics Inc HKSE:02898
11 GF Score
Price HK$6.39
! 1 Warning Sign
View Full Analysis

What is Sunho Biologics Other Current Receivables?

Sunho Biologics HKSE:02898 11 Other Current Receivables is HK$7.13 Mil as of Jun. 2025. GuruFocus rates HKSE:02898 with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

Sunho Biologics's Other Current Receivables for the quarter that ended in Jun. 2025 was HK$7.13 Mil.

Sunho Biologics's quarterly Other Current Receivables declined from Jun. 2024 (HK$9.98 Mil) to Dec. 2024 (HK$6.52 Mil) but then increased from Dec. 2024 (HK$6.52 Mil) to Jun. 2025 (HK$7.13 Mil).

Sunho Biologics's annual Other Current Receivables declined from Dec. 2022 (HK$1.12 Mil) to Dec. 2023 (HK$1.10 Mil) but then increased from Dec. 2023 (HK$1.10 Mil) to Dec. 2024 (HK$6.52 Mil).

Sunho Biologics Other Current Receivables Related Terms

Sunho Biologics Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Sunho Biologics's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sunho Biologics Other Current Receivables Chart

Sunho Biologics Annual Data
Trend Dec22 Dec23 Dec24
Other Current Receivables
1.12 1.10 6.52

Sunho Biologics Quarterly Data
Jun23 Jun24 Dec24 Jun25
Other Current Receivables 0.00 9.98 6.52 7.13
HKSE:02898
11GF Score
Sunho Biologics Inc HKSE:02898
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sunho Biologics Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of HK$7.13 Mil mean?
Sunho Biologics (HKSE:02898) has a Other Current Receivables of HK$7.13 Mil as of Jun. 2025. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Sunho Biologics and its competitors.
Is Sunho Biologics' Other Current Receivables too high?
Sunho Biologics' current Other Current Receivables is HK$7.13 Mil. Overall, Sunho Biologics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Sunho Biologics' Other Current Receivables compare to VRTX and REGN?
Sunho Biologics' Other Current Receivables of HK$7.13 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Sunho Biologics and its competitors. Sunho Biologics's current Other Current Receivables is HK$7.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunho Biologics stock overvalued right now?
Sunho Biologics (HKSE:02898) has a current Other Current Receivables of HK$7.13 Mil. The current Other Current Receivables is HK$7.13 Mil. Sunho Biologics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Sunho Biologics (HKSE:02898), the current Other Current Receivables is HK$7.13 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sunho Biologics Business Description

Address No. 198 Peninsula Middle Road, Dipu Street, Room 302, Building 3, Anji County, Zhejiang Province, Huzhou, CHN
Sunho Biologics Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development and commercialization of biologics for the treatment of cancers and autoimmune diseases. It has three Core Products, IAH0968, IAP0971, and IAE0972, all of which are developed in-house. IAH0968 is an antibody-dependent cell-mediated cytotoxicity (ADCC) enhanced monoclonal antibody (mAb), and the company has initiated Phase II clinical trials for biliary tract carcinoma (BTC) and colorectal cancer (CRC). IAP0971 and IAE0972 are both immunocytokines and It has completed Phase I clinical trials for advanced solid tumors including non-small cell lung cancer (NSCLC) and CRC.
11GF Score

Get the complete analysis for HKSE:02898

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$6.39
Price